Physician profile
Mary K Locklear
NPI 1063171270
$1,653.91
in general payments reported to CMS, 2019-2025
20 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $246 · 2023: $637 · 2024: $585 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $356.08 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $239.28 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $209.58 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $150.22 | 2022-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.61 | 2022-2024 | Jardiance |
| Abbvie INC. | $91.82 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $80.46 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $74.72 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.58 | 2022-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $45.90 | 2023-2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $34.77 | 2023-2024 | Tymlos |
| Merck Sharp & Dohme LLC | $30.67 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Photonicare INC | $22.96 | 2025 | Otosight Middle Ear Scope |
| Abbott Laboratories | $22.30 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $21.56 | 2023 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $17.69 | 2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $14.64 | 2024 | Voquezna |
| Exact Sciences Corporation | $14.14 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $14.03 | 2023 | Gemtesa |
| Mylan Specialty L.P. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.